➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Patent: 10,066,003

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,066,003
Title:Peptides and combination of peptides for use in immunotherapy against various tumors
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s): Mahr; Andrea (Tubingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tubingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Houston, TX), Stevermann; Lea (Tubingen, DE)
Application Number:15/953,128
Patent Claims:see list of patent claims

Details for Patent 10,066,003

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ⤷  Free Forever Trial IMMATICS BIOTECHNOLOGIES GMBH (Tubingen, DE) 2035-03-27 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ⤷  Free Forever Trial IMMATICS BIOTECHNOLOGIES GMBH (Tubingen, DE) 2035-03-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,066,003

Country Patent Number Estimated Expiration
Argentina 104113 ⤷  Free Forever Trial
Argentina 112781 ⤷  Free Forever Trial
Australia 2016239920 ⤷  Free Forever Trial
Australia 2018232952 ⤷  Free Forever Trial
Australia 2019202561 ⤷  Free Forever Trial
Australia 2019222976 ⤷  Free Forever Trial
Australia 2020256298 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.